Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Begins Phase I Testing of Hemophilia Drug

Premium

Alnylam Pharmaceuticals this week announced that it has begun a phase I trial of ALN-AT3, an RNAi-based treatment for hemophilia and other bleeding disorders.

The drug is designed to silence antithrombin and is administered using the company's GalNAc conjugates, which enable subcutaneous delivery.

The phase I trial is being conducted in the UK and is structured in two parts. The first will test single escalating doses of ALN-AT3 in 24 healthy volunteers, and will examine the agent's safety, as well as changes in antithrombin plasma levels at sub-pharmacologic doses.

The second part will evaluate multiple escalating doses of ALN-AT3 in 18 patients with moderate to severe hemophilia A or B. The primary objective of this arm of the trial is examine safety and tolerability, as well as clinical activity as determined by the knockdown of circulating antithrombin levels and increase in thrombin generation at pharmacologic doses.

Initial data from the study is expected to be released in late 2014.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more